HEPARIN AND HEPARAN-SULFATE ENHANCEMENT OF THE INHIBITORY ACTIVITY OF PLASMINOGEN-ACTIVATOR INHIBITOR TYPE-1 TOWARD UROKINASE-TYPE PLASMINOGEN-ACTIVATOR

被引:7
作者
URANO, T
SERIZAWA, K
TAKADA, Y
TOR, N
TAKADA, A
机构
[1] HAMAMATSU UNIV SCH MED, DEPT PHYSIOL, HAMAMATSU, SHIZUOKA 43131, JAPAN
[2] UMEA UNIV, DEPT CELL & MOLEC BIOL, UMEA, SWEDEN
来源
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS | 1994年 / 1201卷 / 02期
关键词
PLASMINOGEN ACTIVATOR INHIBITOR TYPE 1; UROKINASE TYPE PLASMINOGEN ACTIVATOR; HEPARIN; HEPARAN SULFATE;
D O I
10.1016/0304-4165(94)90043-4
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
To study effects of glycosaminoglycan on the interaction between two chain urokinase type plasminogen activator (tcu-PA) (EC 3.4.21.31) and plasminogen activator inhibitor type 1 (PAI-I) the second order rate constant (k(1)) between high molecular weight tcu-PA and active recombinant prokaryotic PAI-1 (rpPAI-1) was determined employing a continuous method using chromogenic substrate S-2444 either in the presence or absence of various kinds of glycosaminoglycans. k(1) was (5.9 +/- 1.6) 10(6)/mol per s in the absence of effector molecule, and following addition of heparin (1.0 U/ml) k(1) was enhanced to (3.22 +/- 0.73).10(7). A significant enhancement of k(1) was also obtained by heparan sulfate (1.87 +/- 0.25).10(7). Dermatan sulfate or chondroitin sulfate did not show a significant effect on k(1) although a slight decrease was obtained by mono-dextran sulfate (4.2 +/- 1.2).10(6). The intrinsic fluorescence of rpPAI-1 was shown to be slightly increased following addition of heparin (1.49 +/- 0.22%, n = 6), suggesting that heparin may enhance the inhibitory activity of PAI-1 toward tcu-PA both by a template mechanism and by a modification of PAI-1 structure.
引用
收藏
页码:217 / 222
页数:6
相关论文
共 45 条
[31]   RELATIONSHIP BETWEEN TISSUE PLASMINOGEN-ACTIVATOR AND THE ACTIVATORS IN BLOOD AND VASCULAR WALL [J].
RIJKEN, DC ;
WIJNGAARDS, G ;
WELBERGEN, J .
THROMBOSIS RESEARCH, 1980, 18 (06) :815-830
[32]  
RYDZEWSKI A, 1989, THROMB HAEMOSTASIS, V62, P752
[33]  
SANCHO E, 1993, THROMB HAEMOSTASIS, V69, P1326
[34]   HEPARIN BINDING TO THE UROKINASE KRINGLE DOMAIN [J].
STEPHENS, RW ;
BOKMAN, AM ;
MYOHANEN, HT ;
REISBERG, T ;
TAPIOVAARA, H ;
PEDERSEN, N ;
GRONDAHLHANSEN, J ;
LLINAS, M ;
VAHERI, A .
BIOCHEMISTRY, 1992, 31 (33) :7572-7579
[35]  
STRANDBERG L, 1991, J BIOL CHEM, V266, P13852
[36]   PLASMINOGEN-ACTIVATOR SYSTEM IN HUMAN BREAST-CANCER [J].
SUMIYOSHI, K ;
SERIZAWA, K ;
URANO, T ;
TAKADA, Y ;
TAKADA, A ;
BABA, S .
INTERNATIONAL JOURNAL OF CANCER, 1992, 50 (03) :345-348
[37]   KINETICS OF INHIBITION OF TISSUE-TYPE AND UROKINASE-TYPE PLASMINOGEN-ACTIVATOR BY PLASMINOGEN-ACTIVATOR INHIBITOR TYPE-1 AND TYPE-2 [J].
THORSEN, S ;
PHILIPS, M ;
SELMER, J ;
LECANDER, I ;
ASTEDT, B .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1988, 175 (01) :33-39
[38]   HUMAN-PLASMA PROTEINASE-INHIBITORS [J].
TRAVIS, J ;
SALVESEN, GS .
ANNUAL REVIEW OF BIOCHEMISTRY, 1983, 52 :655-709
[39]  
URANO T, 1987, J BIOL CHEM, V262, P15959
[40]   THE RECIPROCAL EFFECTS OF EPSILON-AMINOHEXANOIC ACID AND CHLORIDE-ION ON THE ACTIVATION OF HUMAN (GLU1]PLASMINOGEN BY HUMAN UROKINASE [J].
URANO, T ;
CHIBBER, BAK ;
CASTELLINO, FJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1987, 84 (12) :4031-4034